2024-07-11Zeitschriftenartikel
Increase of Synergistic Secondary Antiviral Mutations in the Evolution of A(H1N1)pdm09 Influenza Virus Neuraminidases
| dc.contributor.author | Duwe, Susanne C. | |
| dc.contributor.author | Milde, Jeanette | |
| dc.contributor.author | Heider, Alla | |
| dc.contributor.author | Wedde, Marianne | |
| dc.contributor.author | Schweiger, Brunhilde | |
| dc.contributor.author | Dürrwald, Ralf | |
| dc.date.accessioned | 2026-03-17T13:48:18Z | |
| dc.date.available | 2026-03-17T13:48:18Z | |
| dc.date.issued | 2024-07-11 | none |
| dc.identifier.other | 10.3390/v16071109 | |
| dc.identifier.uri | http://edoc.rki.de/176904/13558 | |
| dc.description.abstract | The unexpected emergence of oseltamivir-resistant A(H1N1) viruses in 2008 was facilitated in part by the establishment of permissive secondary neuraminidase (NA) substitutions that compensated for the fitness loss due to the NA-H275Y resistance substitution. These viruses were replaced in 2009 by oseltamivir-susceptible A(H1N1)pdm09 influenza viruses. Genetic analysis and screening of A(H1N1)pdm09 viruses circulating in Germany between 2009 and 2024 were conducted to identify any potentially synergistic or resistance-associated NA substitutions. Selected viruses were then subjected to further characterization in vitro. In the NA gene of circulating A(H1N1)pdm09 viruses, two secondary substitutions, NA-V241I and NA-N369K, were identified. These substitutions demonstrated a stable lineage in phylogenetic analysis since the 2010–2011 influenza season. The data indicate a slight increase in viral NA bearing two additional potentially synergistic substitutions, NA-I223V and NA-S247N, in the 2023–2024 season, which both result in a slight reduction in susceptibility to NA inhibitors. The accumulation of secondary synergistic substitutions in the NA of A(H1N1)pdm09 viruses increases the probability of the emergence of antiviral-resistant viruses. Therefore, it is crucial to closely monitor the evolution of circulating influenza viruses and to develop additional antiviral drugs against different target proteins. | eng |
| dc.language.iso | eng | none |
| dc.publisher | Robert Koch-Institut | |
| dc.rights | (CC BY 3.0 DE) Namensnennung 3.0 Deutschland | ger |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/de/ | |
| dc.subject | influenza viruses | eng |
| dc.subject | A(H1N1)pdm09 | eng |
| dc.subject | neuraminidase inhibitor | eng |
| dc.subject | surveillance | eng |
| dc.subject | resistance | eng |
| dc.subject | monitoring | eng |
| dc.subject | oseltamivir | eng |
| dc.subject | permissive mutations | eng |
| dc.subject | secondary mutations | eng |
| dc.subject.ddc | 610 Medizin und Gesundheit | none |
| dc.title | Increase of Synergistic Secondary Antiviral Mutations in the Evolution of A(H1N1)pdm09 Influenza Virus Neuraminidases | none |
| dc.type | article | |
| dc.identifier.urn | urn:nbn:de:0257-176904/13558-1 | |
| dc.type.version | publishedVersion | none |
| local.edoc.container-title | Viruses | none |
| local.edoc.type-name | Zeitschriftenartikel | |
| local.edoc.container-type | periodical | |
| local.edoc.container-type-name | Zeitschrift | |
| local.edoc.container-publisher-name | MDPI | none |
| local.edoc.container-reportyear | 2024 | none |
| local.edoc.container-firstpage | 1 | none |
| local.edoc.container-lastpage | 11 | none |
| dc.description.version | Peer Reviewed | none |
